Abstract: A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010.
Type:
Application
Filed:
December 23, 2013
Publication date:
July 3, 2014
Applicants:
Rose Pharma A/S, MannKind Corporation
Inventors:
Peter Richardson, Edna Kenny, Per Hellstrom, Marshall L. Grant, Grayson W. Stowell, Scott Daniels, Anthony Smithson, Stephanie Greene
Abstract: Provided is a method for the synthesis of N-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.
Type:
Grant
Filed:
March 16, 2012
Date of Patent:
June 10, 2014
Assignee:
MannKind Corporation
Inventors:
John J. Stevenson, Destardi Moye-Sherman
Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.
Type:
Grant
Filed:
June 11, 2010
Date of Patent:
May 27, 2014
Assignee:
Mannkind Corporation
Inventors:
Marshall L. Grant, Grayson W. Stowell, Paul Menkin
Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties.
Abstract: Embodiments of the invention disclosed herein relate to methods and compositions for bypassing the involvement of CD4+ cells when generating antibody and MHC class I-restricted immune responses, controlling the nature and magnitude of the response, and promoting effective immunologic intervention in viral pathogenesis. More specifically, embodiments relate to immunogenic compositions for vaccination particularly therapeutic vaccination, against HIV and other microbial pathogens that impact functioning of the immune system, their nature, and the order, timing, and route of administration by which they are effectively used.
Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
Type:
Application
Filed:
December 10, 2013
Publication date:
April 10, 2014
Applicant:
MannKind Corporation
Inventors:
Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.
Type:
Application
Filed:
November 27, 2013
Publication date:
March 27, 2014
Applicant:
MannKind Corporation
Inventors:
Chad C. Smutney, P. Spencer Kinsey, Carl R. Sahi, Benoit Adamo, John M. Polidoro, Scott McLean, Dennis Overfield, Anthony Bryant, Tom He, Alfred Mann
Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
Type:
Application
Filed:
November 13, 2013
Publication date:
March 20, 2014
Applicant:
MANNKIND CORPORATION
Inventors:
John Bruce PATTERSON, David Gregory LONERGAN, Gary A. FLYNN, Qingping ZENG, Peter V. PALLAI
Abstract: Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.
Type:
Application
Filed:
November 11, 2013
Publication date:
March 20, 2014
Applicant:
MannKind Corporation
Inventors:
Gary A. Flynn, Sandra A. Lee, Mary Faris, David W. Brandt, Subrata Chakravarty
Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
Type:
Grant
Filed:
May 25, 2012
Date of Patent:
February 18, 2014
Assignee:
MannKind Corporation
Inventors:
Liping Liu, Adrian Ion Bot, David C. Diamond
Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.
Type:
Application
Filed:
September 3, 2013
Publication date:
February 13, 2014
Applicant:
MannKind Corporation
Inventors:
Marshall L. Grant, Grayson W. Stowell, Paul Menkin
Abstract: Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.
Type:
Application
Filed:
October 29, 2013
Publication date:
February 13, 2014
Applicant:
MannKind Corporation
Inventors:
Edwin Amoro, Karel Vanackere, Michael A. White
Abstract: A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010.
Type:
Grant
Filed:
August 5, 2010
Date of Patent:
February 4, 2014
Assignee:
Mannkind Corporation
Inventors:
Peter Richardson, Enda Kenny, Per Hellstrom, Marshall L. Grant, Grayson W. Stowell, Scott Daniels, Anthony Smithson, Stephanie Greene
Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.
Type:
Grant
Filed:
June 12, 2009
Date of Patent:
January 28, 2014
Assignee:
Mannkind Corporation
Inventors:
Chad C. Smutney, P. Spencer Kinsey, Carl R. Sahi, Benoit Adamo, John M. Polidoro, Scott McLean, Dennis Overfileld, Anthony Bryant, Tom He, Alfred Mann
Abstract: The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette. The housekeeping epitope(s) can be derived from a target-associated antigen, and the housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.
Type:
Grant
Filed:
November 7, 2002
Date of Patent:
January 28, 2014
Assignee:
Mannkind Corporation
Inventors:
John J. L. Simard, David C. Diamond, Zhiyong Qiu, Xiang-Dong Lei
Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.
Type:
Application
Filed:
June 18, 2013
Publication date:
January 9, 2014
Applicant:
MannKind Corporation
Inventors:
Chad C. Smutney, P. Spencer Kinsey, Carl R. Sahi, Benoit Adamo, John M. Polidoro, Scott McLean, Dennis Overfield, Kelly S. Kraft, Karla Somerville
Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
Type:
Grant
Filed:
January 17, 2012
Date of Patent:
January 7, 2014
Assignee:
Mannkind Corporation
Inventors:
Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
Type:
Grant
Filed:
November 8, 2010
Date of Patent:
December 24, 2013
Assignee:
MannKind Corporation
Inventors:
John Bruce Patterson, David Gregory Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.
Type:
Application
Filed:
July 30, 2013
Publication date:
December 19, 2013
Applicant:
MannKind Corporation
Inventors:
Chad C. Smutney, P. Spencer Kinsey, Carl R. Sahi, Benoit Adamo, John M. Polidoro, Scott McLean, Dennis Overfield, Kelly S. Kraft, Karla Somerville